The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.
The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...
The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...
Glargine U300 use was common, especially with increased CKD stages and baseline HbA1c levels among patients with type 2 diabetes.
Tips for diabetics fasting during Ramadan: test blood sugar, adjust insulin dosage, monitor symptoms, consult doctor if ...
23hon MSN
Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...
Tandem Diabetes Care (Nasdaq:TNDM) today announced positive data supporting its automated insulin delivery technology for ...
Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025MBX 1416 Phase 2 trial in ...
AI-enhanced glucose monitoring provides predictive analytics and personalized insights for better blood sugar management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback